Novavax (NVAX) stock analysis, July 24, 2025: NVAX bounces 16.87% in a month, but BofA cuts target to $9

Current Trend

Novavax (NVAX) shares show mixed dynamics, with a short-term bounce amid a longer-term downtrend. At $7.58, the stock is down YTD (-5.66%) and has fallen 17.73% over the past six months. However, it rallied 16.87% in the last month and 8.36% over the past five days, suggesting a possible trend reversal or a technical correction.

Investment Thesis

Novavax is attractive as an alternative vaccine maker with a potentially safer profile. The company is developing protein-based vaccines for COVID-19 and influenza, which could give it a competitive edge as the vaccine market evolves and safety demands rise.

Thesis Status

The thesis is partially realized. Positive clinical trial results validate the scientific approach, but analysts’ lower price targets highlight ongoing commercialization and competitive challenges.

Key Drivers

• Bank of America cut its price target from $10 to $9 while keeping a “Neutral” rating (CNN/TipRanks, GuruFocus) • Positive COVID-19 vaccine data showing fewer side effects than Pfizer’s mRNA shot (CNN/TipRanks) • Development of combined COVID-19 and flu vaccines

Technical Picture

The stock is in a short-term recovery phase after a prolonged decline. At $7.58 it sits below the revised analyst target of $9, leaving roughly 18.7% upside. A strong monthly gain (16.87%) amid heightened volatility points to active investor interest at current levels.

Bull Case

1. Improved safety profile: The COVID-19 vaccine shows fewer side effects than Pfizer’s mRNA product (CNN/TipRanks) 2. Technical bounce: Gains of 16.87% over the month and 8.36% over five days suggest upward momentum 3. Discount to target: Current price is 18.7% below BofA’s revised $9 target 4. Innovative platform: Combined COVID-19/flu vaccine development could open new markets 5. Positive clinical data: Encouraging trial results strengthen the company’s scientific foundation (CNN/TipRanks)

Bear Case

1. Analyst target cuts: BofA lowered its price target by 10% to $9, maintaining a neutral rating (GuruFocus) 2. Long-term decline: A 17.73% drop over six months signals structural challenges 3. Current pullback: A 3.25% dip today indicates lingering seller pressure 4. Negative YTD performance: YTD return of -5.66% reflects weak fundamentals 5. Neutral analyst stance: BofA’s neutral rating suggests no strong growth catalysts currently.